• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Video

May 8, 2023

Colorectal Cancer Trends Increasingly Younger at Age of Diagnosis, Making Effective Early Intervention Critical

Kimlin Tam Ashing, PhD, discusses her research assessing effective interventions in ethnic minority communities to increase colorectal cancer screenings.

Pharmacy Times® interviewed Kimlin Tam Ashing, PhD, a professor and founding director of the Center of Community Alliance for Research & Education (CCARE) at City of Hope, who is a leader in examining health disparities, cancer inequities, survivorship, and quality of life in oncology care and presented her research at the 114th Annual Meeting of the American Association for Cancer Research (AACR). Ashing presented at AACR on how interventions in ethnic minority communities elucidate strategies for increasing colorectal cancer screenings, and how community outreach and engagement increases colorectal cancer screening in ethnic minority communities.

Pharmacy Times: Why was colorectal cancer screening a particular focus for your team at City of Hope?

Kimlin Tam Ashing, PhD: Colorectal cancer has been on the increase across the US and actually globally. So, it's critically important to address prevention. In particular, it's one of the cancers in the sense that we have screenings that actually could detect the cancer before it spreads. We can detect even cellular changes before it becomes cancer, which is the colonoscopy. So, it's one of the cancers that we can really make an impact on in terms of prevention, early detection, and screening and saving lives. We see a trend for earlier stage of diagnosis if we screen appropriately.

Unfortunately, it’s one of the cancers where we see a trend in increasing younger age of diagnosis. So, we are particularly excited that the US Preventive Task Force has reduced the age from 50 to 45. And so, we want to make that very much a part of the public awareness and domain for cancer prevention.

Pharmacy Times: Could you tell me more about the multi-component intervention between October 2020 and October 2022?

Ashing: Yes, so understanding that there multi-level factors that influence colorectal cancer screening, as well as other cancer screenings, right? So, we understand that the system level factors are critically important. We looked at Federally Qualified Health Centers [FQHCs], which are federally qualified health clinics, to provide much of the preventive care for our medically underserved populations. So, that was one of the target groups in terms of working with workflows and physician recommendation that has been deemed as evidence-based increased colorectal cancer screening.

We know that public awareness is critically important, so we leveraged our ethnically focused media because our population who tend to be more likely to be not up to date with screening or lacking access to care—we promoted this through several media campaigns that target various Asian communities, the African American community, the Latinx community, through radio, local television, as well as social media to reach those populations so that there is increased awareness of colorectal cancer, colorectal cancer screening, and the importance of early detection and screening. So, we implemented also the multimedia campaign.

We also worked with community leaders in the various organizations that we partner with, including nurse associations and local advocacy organizations. So, we were able to train and activate their community advocates, their community leaders so that they can spread the word about colorectal cancer screenings. So, it’s multi-component, addressing the different aspects of the clinic system, the provider communication, activating applicants to spread the word, and also public media campaigns, so capturing people where they are to activate them into screening.

Pharmacy Times: Would these interventions be possible to implement without partnership with FQHCs and community and faith-based organizations?

Ashing: I think as cancer centers, we can make some impact alone, but we can go much further together. We really need to include those who are boots-on-the-ground, who have trust and credibility and trustworthiness in the community. So, partnering with the organizations that can help us do the important work of addressing cancer burden and disparities in our communities, I think it’s critically important, these partnerships. As comprehensive cancer centers, we are doing an incredibly good job of working in communities as community outreach and engagement staff and experts, but we need the partnerships in order to reach are very, very hard to reach population and those communities for whom there are various, including lack of awareness of cancer screening.

There may be beliefs around cancer that needs to have someone who is a community gatekeeper to, you know, actually challenge some of those beliefs. The fact that many communities still tend to think that cancer screening is looking for cancer, so that if you screen, you're actually gonna find something that doesn't exist. And so, there may be these beliefs that need to be appropriately respected but challenged, and say, that cancer screening actually detects changes that could become cancer or are already cancerous. And that this can allow you to have timely treatments, preventive treatments if it's pre-cancerous, as well as reduce the burden and the challenge and the human impact of extended cancer treatments if we find it early, and extend lives and improve quality of life. So, we need these trusted community partners to also work with us to address the cultural as well as the community barriers. And we also need the systems to address the system barriers, just looking at the importance of physician reminders, that every opportunity for an in-person visit or virtual visit is an opportunity to recommend cancer screening that’s due.

Pharmacy Times: What were the results of the multi-component interventions during the 2-year study period, and how were these results assessed?

Ashing: Yes, so we found that our multi-prong intervention was effective in addressing the physician priority of recommending cancer screening, that these health systems were very much welcoming and realized that there are opportunities for improvement, right—quality improvements in terms of cancer screening recommendations. And so, we found that, based on this intervention, that we were able to screen an additional almost 600 persons that would not have been screened without the intervention. And so, we were very rigorous and conservative in our analyses. And we also found that, of course, where you would find that the community clinics that were really challenged to address colorectal cancer screening, that they had important improvements, but that there are system changes, right, and system differences that need to be recognized, because not all clinics start at the same point. And some clinics may need longer intervention, additional support for workflows to increase the cancer screening, so that it gets to be at least the Healthy People recommendation.

Pharmacy Times: For organizations interested in establishing similar interventions to improve colorectal cancer screening, how would you recommend they start this process and find the right partnerships to have a significant impact in their communities?

Ashing: It's important to partner with community organizations. I think making contact—most community organizations in our experience are ready and willing to partner. Our community leaders recognize that cancer screening and prevention is under-addressed and understudied in our marginalized and minoritized communities. So, they are ready and willing. It just takes the brave step of reaching out to community partners. I think organizations such as the American Cancer Society, is a great partner to introduce cancer centers and researchers to community partners who are willing.

Also, our FQHC partners are also very open to quality improvement. These are important metrics for these centers to report, so they are very, very willing to partner. And, I think, an openness to dialogue—so before we started, we actually worked with these community partners in developing the project and developing the protocol. In terms of responding to what the needs are, I think it's important to reach out and get feedback and input from all of the sectors who are going to be impacted by the intervention and have them at the table so that we are both listening and responding to the needs of the community.

Related Videos
Image credit: Dr_Microbe | stock.adobe.com
Image credit: komokvm | stock.adobe.com
Vial of Pneumococcal vaccine - Image credit: Bernard Chantal | stock.adobe.com
Related Content
Advertisement
NLA 2025: Data on ApoC3 Inhibitors Shows Promise Across a Spectrum of Hypertriglyceridemic Disorders
May 31st 2025

NLA 2025: Data on ApoC3 Inhibitors Shows Promise Across a Spectrum of Hypertriglyceridemic Disorders

Alana Hippensteele, Lead Editor
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Illustration of myocardial infarction
May 30th 2025

NLA 2025: Inclisiran With Standard Care Provides Rapid, Sustained Lowering of LDL-C in Patients With Recent Acute Coronary Syndrome

Luke Halpern, Assistant Editor
pharmacy focus oncology podcast
May 19th 2025

Insights from a Pharmacy Times Peer Exchange: Real-World Outcomes and Supportive Care

Alexandra Gerlach, Associate Editor
Woman can't eat bread and grain products because of gluten intolerance. A young celiac woman suffers from abdominal pain after eating fresh bread - Image credit: weyo | stock.adobe.com
May 30th 2025

FDA Grants Fast Track Designation to Drug Candidate for Celiac Disease

Kennedy Ferruggia, Assistant Editor
Washington, DC, USA - June 24, 2022: The symbol of the U.S. Department of Health and Human Services is seen at the entrance to its headquarters in the Hubert H. Humphrey Building in Washington, DC
May 30th 2025

HHS Cancels Millions in Pandemic Influenza mRNA Vaccine Development Grants

Luke Halpern, Assistant Editor
Related Content
Advertisement
NLA 2025: Data on ApoC3 Inhibitors Shows Promise Across a Spectrum of Hypertriglyceridemic Disorders
May 31st 2025

NLA 2025: Data on ApoC3 Inhibitors Shows Promise Across a Spectrum of Hypertriglyceridemic Disorders

Alana Hippensteele, Lead Editor
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Illustration of myocardial infarction
May 30th 2025

NLA 2025: Inclisiran With Standard Care Provides Rapid, Sustained Lowering of LDL-C in Patients With Recent Acute Coronary Syndrome

Luke Halpern, Assistant Editor
pharmacy focus oncology podcast
May 19th 2025

Insights from a Pharmacy Times Peer Exchange: Real-World Outcomes and Supportive Care

Alexandra Gerlach, Associate Editor
Woman can't eat bread and grain products because of gluten intolerance. A young celiac woman suffers from abdominal pain after eating fresh bread - Image credit: weyo | stock.adobe.com
May 30th 2025

FDA Grants Fast Track Designation to Drug Candidate for Celiac Disease

Kennedy Ferruggia, Assistant Editor
Washington, DC, USA - June 24, 2022: The symbol of the U.S. Department of Health and Human Services is seen at the entrance to its headquarters in the Hubert H. Humphrey Building in Washington, DC
May 30th 2025

HHS Cancels Millions in Pandemic Influenza mRNA Vaccine Development Grants

Luke Halpern, Assistant Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.